- cafead   Sep 25, 2023 at 08:22: PM
via After a complete response letter and delayed preapproval inspections, the FDA found a fresh problem at a clinical trial site for Coherus’ Junshi Biosciences-partnered toripalimab, Coherus said Monday.
article source
article source